Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Badger Meter Inc (BMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Badger Meter Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Badger Meter Inc trades at $141.27 (market cap $4.21B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.5× Badger Meter Inc's market cap, and Badger Meter Inc pays a 1.11% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BMI | |
|---|---|---|
Market Cap | $39.89B | $4.21B |
Sector | Health | Technology |
52-Week High | $491.22 | $245.81 |
52-Week Low | $278.09 | $113.41 |
Enterprise Value | $38.15B | $4.00B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Badger Meter (BMI) trades at $144.18, down 0.54% today, with a bullish technical outlook supported by moving averages and strong ADX readings. The company maintains solid profitability with 14.56% net margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create near-term uncertainty. Revenue declined to $897M in 2026 from $917M in 2025, while cash flow improved to positive $74M.
BMI presents a mixed investment case with strong fundamentals offset by legal risks. The stock trades near analyst consensus target of $144.80, offering limited upside. While operational metrics remain healthy, the pending class action and recent earnings volatility warrant caution. Institutional sentiment leans neutral with 55.55% hold ratings, suggesting investors await legal resolution and earnings stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →
